Open AccessEfficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country
Author(s) -
Tarek Assi,
Joseph Kattan,
Elie El Rassy,
Samer Tabchi,
Ralph Chebib,
Tania Moussa,
Colette Hanna,
Fadi El Karak,
Fadi Farhat,
Marwan Ghosn
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.183552
Subject(s) - medicine , exemestane , everolimus , breast cancer , oncology , cancer , population , hormonal therapy , aromatase , environmental health
Breast cancer is the second leading cause of cancer-related mortality despite the staggering improvement in cancer therapeutics. So far, published data illustrate endocrine therapy as the cornerstone treatment for patients with hormone receptor-positive metastatic breast cancer. Unfortunately, most patients eventually develop resistance to this treatment.